Published in Cancer Weekly, August 16th, 1999
M. Selmayr and colleagues from Germany and Belgium developed a strategy to circumvent obstacles associated with using lymphoma idiotype (Id) to produce an engineered vaccine to treat B cell lymphoma ("Induction of Tumor Immunity by Autologous B Lymphoma Cells Expressing a Genetically Engineered Idiotype," Gene Therapy, 1999;6(5):778-84).
"We have developed a strategy that allows the expression of an Id/GM-CSF fusion protein in an autologous lymphoma cell," wrote Selmayr...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.